SEC Form 4 · accession 0001209191-15-048520
Juno Therapeutics, Inc. · JUNO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hyam Levitsky
Officer — See Remarks
Period of report
May 28, 2015
Accepted (ET)
Jun 1, 2015 · 8:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001594864
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 28, 2015 | A | 145,000 | $0.00 | A | 145,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $50.60 | May 28, 2015 | A | 175,000 | A | — | May 27, 2025 | Common Stock | 175,000 | 175,000 | D |
Explanation of responses
- F1Represents restricted stock units ("RSUs") granted pursuant to the 2014 Equity Incentive Plan. 47,500 of the RSUs vest on May 27, 2016 and 32,500 of the RSUs vest annually thereafter.
- F225% of the shares subject to the option become vested and exercisable on May 27, 2016 and 1/48 of the shares subject to the option shall vest and become exercisable monthly thereafter.
Remarks
Executive Vice President, Research and Chief Scientific Officer